Ivím Health

Ivím posts clear starting prices for compounded GLP‑1s—semaglutide from $99/month and tirzepatide from $149/month—plus a required $74.99 monthly membership. Liraglutide is listed from $249/month. We verified these on the GLP‑1 ID page and a pricing FAQ (updated August 1, 2025). For most compounding‑eligible patients, all‑in costs remain predictable: membership + medication + optional add‑ons (e.g., lipotropics, sermorelin, NAD+). Strengths: the company communicates that compounded medications are not FDA‑approved and keeps program fees prominent alongside medication pricing. This reduces ‘sticker shock’ later. Trade‑offs: programs often carry a multi‑month commitment, effectively locking in membership fees for the term; refunds for unshipped items may incur restocking fees, and shipped medications are non‑refundable. Overall, Ivím lands in the “good value” tier for compound access, with high transparency but less flexibility than month‑to‑month models.

Ivím’s care model emphasizes weekly provider oversight and individualized dosing. Pharmacy partners are described as USP‑compliant and PCAB‑compliant, with facilities under FDA regulation, and the site provides safety information clarifying that compounded GLP‑1s are not FDA‑approved. The HIPAA Notice details covered‑entity structures and data governance for medical information. In practice, using multiple pharmacies helps continuity of supply but introduces variability in packaging and fulfillment experience. We view Ivím’s stated quality controls and clinical cadence as solid for a compounding‑first program; the main quality risk is the inherent variability of supply chains and the non‑FDA‑approved status of compounds, which Ivím discloses.

Onboarding follows a straightforward path: eligibility questionnaire → virtual consult (video or chat) → program selection and payment → pharmacy fulfillment. The company highlights weekly check‑ins through its app and ample provider access included in membership. Public reviews frequently mention smooth consults and clear explanations at intake. Where friction emerges is after the consult: once invoices are paid, pharmacies generally need 10–14 days to process and ship. This expectation is documented, but prospective patients must plan for it—especially before travel or dose transitions. Overall, Ivím’s intake and consult flow is intuitive and well‑scaffolded, with the main pacing constraint at the pharmacy stage.

Ivím offers compounded semaglutide, tirzepatide, and liraglutide, plus access to brand GLP‑1s (e.g., Wegovy®, Zepbound®) via a traditional program when clinically appropriate. The GLP‑1 ID model emphasizes flexible, individualized dosing with weekly adjustments—useful for tolerability and side‑effect management. Compounded options broaden access and budget control but are not FDA‑approved; Ivím states this repeatedly and links to safety information. Add‑on therapies (lipotropics, sermorelin, NAD+) are optional. Overall, the platform covers most GLP‑1 use cases for self‑pay patients; it may be less ideal if brand‑only coverage through insurance is a must, or if compounding is unavailable in a patient’s state.

Ivím states that once invoices are paid, pharmacies typically process, fill, and ship orders within 10–14 days (longer around weekends/holidays). Carriers include UPS or FedEx with door‑to‑door delivery and tracking. This aligns with many compounding workflows and sets a clear expectation for patients to order proactively. We also observed reports of variable timelines—some quicker, some slower—especially during spikes in demand or when partner pharmacies change. Patients who need rapid, just‑in‑time refills should plan ahead or consider programs with guaranteed faster turnaround.

Ivím markets “unlimited” access to providers and a responsive care team. Public review profiles show a very high volume of positive feedback and frequent company replies (often within hours), supporting strong frontline engagement. Conversely, some public threads describe slower responses and difficulty getting definitive answers during fulfillment delays. We interpret support as generally attentive during clinical interactions but occasionally stretched by pharmacy backlogs. Clearer proactive updates during long fills would boost this score.

The website makes pricing and key inclusions easy to find, and the GLP‑1 ID pages clearly outline the patient journey. Membership benefits and program commitments are called out plainly. The help center is organized and answers common operational questions (timelines, carriers, cancellations). Some users note minor portal friction and would benefit from more real‑time order status detail during the pharmacy window. Overall, a clean experience with room for stronger fulfillment transparency.